ERBB2 and breast carcinoma: Results of our study support the statement of Prat A and colleagues - the intrinsic subtypes can help identify those patients with HER2+ early breast cancer that might be successfully treated without chemotherapy but with dual HER2 blockade since their tumours are fully sensitive to anti-HER2 therapy.